David Calfee, MD, MS, FIDSA
he/him/his
Professor of Internal Medicine (Infectious Diseases)Cards
About
Research
Publications
2026
The Impact of Colistin MIC on Clinical Failure and Mortality: Insights from the OVERCOME Trial
Pogue J, Rybak M, Abdul-Mutakabbir J, Stamper K, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu C, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Paul M, Roilides E, Samarkos M, Sims M, Tancheva D, Tsiodras S, Kett D, Patel G, Calfee D, Leibovici L, Power L, Munoz-Price S, Susick L, Latack K, Chiou C, Divine G, Ghazyaran V, Narayanan N, Kaye K. The Impact of Colistin MIC on Clinical Failure and Mortality: Insights from the OVERCOME Trial. Clinical Microbiology And Infection 2026 PMID: 42250757, DOI: 10.1016/j.cmi.2026.05.046.Peer-Reviewed Original ResearchClinical failureColistin MICsColistin monotherapyCombination therapyCarbapenem-resistant Gram-negative bacilliColistin-based therapyMeropenem combination therapyPlacebo-controlled trialGram-negative bacilliIntensive care unitPost Hoc AnalysisSusceptibility breakpointsA. baumanniiBloodstream infectionsDouble-blindAcinetobacter baumanniiMIC valuesPharmacodynamic limitationsColistinMonotherapyCare unitHoc AnalysisTherapyEssential antibioticsPneumoniaPopulation pharmacokinetics of polymyxin B: an individual participant data meta-analysis
Matcha S, Rao G, Hanafin P, Liu X, Yu Z, Zhang J, Qiu H, Cheng Y, Zavascki A, Sandri A, Kwa A, Scheetz M, Kubin C, Shah J, Cherng B, Yin M, Wang J, Wang L, Calfee D, Bolon M, Purcell A, Nation R, Pogue J, Kaye K, Li J. Population pharmacokinetics of polymyxin B: an individual participant data meta-analysis. Clinical Microbiology And Infection 2026 PMID: 42229684, DOI: 10.1016/j.cmi.2026.05.036.Peer-Reviewed Original ResearchProbability of target attainmentData Meta-AnalysisInterindividual variabilityParticipant data meta-analysisCovariate-parameter relationshipsProbability of target attainment analysisPharmacokinetics of polymyxin BPolymyxin B PKMultiple-dose regimensMeta-analysisPopulation PK modelClinically relevant covariatesPopulation PK analysisCritically ill subjectsVolume of distributionConcentration-time profilesStatistically significant associationPK/pharmacodynamic targetsMIC breakpointsLoading doseNonpulmonary infectionsCreatinine clearanceTarget attainmentTwo-compartment modelIndividual Participant Data Meta-Analysis
2025
Hospital-onset methicillin-resistant Staphylococcus aureus bloodstream infections within tertiary and community hospitals and implications for prevention
Singh H, Ross B, Hannah J, Ting S, Teasdale C, Wang X, Quinn M, Calfee D, Simon M, Torres H, Acker K, Horowitz H, Wang T, Gunawardhana N, Golderg R, Salazar Y, Prasad N, Jagnatnarain N, Johnson C, Kuang D, Gouveia A, Furuya Y, Westervelt K, Saiman L. Hospital-onset methicillin-resistant Staphylococcus aureus bloodstream infections within tertiary and community hospitals and implications for prevention. Infection Control And Hospital Epidemiology 2025, 47: 236-243. PMID: 41363446, PMCID: PMC12932923, DOI: 10.1017/ice.2025.10370.Peer-Reviewed Original ResearchStandardized infection ratioHO-MRSARetrospective cohort studyClinical characteristicsMethicillin-resistant Staphylococcus aureus bloodstream infections, vaMethicillin-resistant Staphylococcus aureus bloodstream infectionsSource of MRSA infectionClinical characteristics of patientsCatheter-related issuesPotential infectious sourcesCharacteristics of patientsMRSA infectionsBSI ratesPatient dischargeBloodstream infectionsPrimary outcomeSecondary outcomesInfectious sourcePatientsCare hospitalMortality rateSystematic surveillanceAcute care hospitalsPrevention strategiesInfectionInvestigation and control of an outbreak of methicillin-susceptible Staphylococcus aureus skin and soft tissue infections in a neonatal intensive care unit.
Rivera-Valenzuela G, Senaldi L, Tiwari P, Yap V, Cannon J, Saiman L, Calfee D, Marino J, Rólon R, Mitchell K, Rowlinson M, Haas W, Sankaranarayanan K, Westblade L, Acker K. Investigation and control of an outbreak of methicillin-susceptible Staphylococcus aureus skin and soft tissue infections in a neonatal intensive care unit. Infection Control And Hospital Epidemiology 2025, 47: 139-144. PMID: 41243561, DOI: 10.1017/ice.2025.10303.Peer-Reviewed Original ResearchMulti-locus sequence typingMethicillin-susceptible Staphylococcus aureus (MSWhole-genome sequencingMethicillin-resistant Staphylococcus aureus (MRNeonatal intensive care unitSoft tissue infectionsStaphylococcus aureus,Intensive care unitMSSA isolatesMulti-locus sequence typing analysisWhole-genome sequence analysisTissue infectionsOutbreak-related strainsMupirocin-resistant isolatesCare unitNon-invasive respiratory supportTransmission eventsNeonatal faceInfection control measuresAssociated with infectionSequence typingMSSA infectionsRespiratory supportPredominant clusterInfectionThe Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
Huralska M, Pogue J, Rybak M, Abdul-Mutakabbir J, Stamper K, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu C, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Paul M, Roilides E, Samarkos M, Sims M, Tancheva D, Tsiodras S, Kett D, Patel G, Calfee D, Leibovici L, Power L, Munoz-Price S, Shaikh H, Susick L, Latack K, Chiou C, Divine G, Ghazyaran V, Kaye K. The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens. Clinical Infectious Diseases 2025, 82: 391-398. PMID: 40682801, PMCID: PMC13016684, DOI: 10.1093/cid/ciaf398.Peer-Reviewed Original ResearchSynergistic combination therapyCarbapenem-resistant Gram-negative bacilliCombination therapyFunctional monotherapyA. baumanniiBloodstream infectionsClinical failureCarbapenem-resistant Gram-negative pathogensIn vitro synergy testingSynergistic therapyLast-line treatmentMicrobiological cure ratesAcinetobacter baumannii infectionsClinical failure rateGram-negative bacilliIn vitro synergyTime-kill analysisSynergistic combination treatmentGram-negative pathogensTreatment of pneumoniaColistin monotherapyColony-forming units/mlSynergy testBaumannii infectionsMicrobiological curePopulation Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity
Hanafin P, Mahadevan R, Rao G, Zavascki A, Sandri A, Kwa A, Scheetz M, Kubin C, Shah J, Cherng B, Yin M, Wang J, Wang L, Calfee D, Bolon M, Purcell A, Nation R, Pogue J, Li J, Kaye K. Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity. Clinical Pharmacology & Therapeutics 2025, 118: 841-852. PMID: 40524377, PMCID: PMC12353974, DOI: 10.1002/cpt.3729.Peer-Reviewed Original ResearchConceptsIntravenous polymyxin BSerum creatinineCritically ill patientsPolymyxin BResistant Gram-negative pathogensDose-limiting adverse effectsIll patientsCritically ill patient populationPolymyxin B dosingRisk of nephrotoxicityLast-line agentsPolymyxin B exposureIll patient populationGram-negative pathogensSensitive to polymyxin B.Clinically relevant treatmentIndirect response modelVancomycin useSupratherapeutic exposuresDrug exposureKidney injuryPatient populationPolymyxin B.Transit compartmentsObservational studyA discrete choice experiment to evaluate healthcare personnel preferences regarding risk-tailored policies for contact precautions for patients with methicillin-resistant Staphylococcus aureus
O’Hara L, Calfee D, Snyder G, Martin E, Angelino N, O’Hara N, Harris A. A discrete choice experiment to evaluate healthcare personnel preferences regarding risk-tailored policies for contact precautions for patients with methicillin-resistant Staphylococcus aureus. Infection Control And Hospital Epidemiology 2025, 46: 710-715. PMID: 40376809, DOI: 10.1017/ice.2025.65.Peer-Reviewed Original ResearchContact precautionsMethicillin-resistant Staphylococcus aureusPrevent MRSA transmissionProbability of uptakeChoice setsPreference policiesHealthcare personnelPolicy optionsMRSA carriageMRSA transmissionHigh-risk settingsPolicyRisk-tailored approachPolicy componentsAdvanced practice providersPatientsEnvironmental services personnelGown useCalculate utilitiesMRSAPractice providersPreferencesUtility scoresHigh-risk activitiesService personnel
2024
Healthcare personnel opinions regarding the feasibility of a risk-tailored approach to contact precautions for methicillin-resistant Staphylococcus aureus in the acute care setting
O’Hara L, Harris A, Calfee D, Snyder G, Cottam J, O’Hara N, Martin E. Healthcare personnel opinions regarding the feasibility of a risk-tailored approach to contact precautions for methicillin-resistant Staphylococcus aureus in the acute care setting. Infection Control And Hospital Epidemiology 2024, 45: 900-902. PMID: 38646712, DOI: 10.1017/ice.2024.54.Peer-Reviewed Original ResearchPutting the “all” in “safe health care for all”
Calfee D. Putting the “all” in “safe health care for all”. Infection Control And Hospital Epidemiology 2024, 45: 420-421. PMID: 38482591, DOI: 10.1017/ice.2024.33.Peer-Reviewed Original ResearchHigh touch surface bioburden associated with the use of disinfectants with and without continuously active disinfection in ambulatory care settings
Torres H, Marino J, Simon M, Singh H, Westblade L, Calfee D. High touch surface bioburden associated with the use of disinfectants with and without continuously active disinfection in ambulatory care settings. Infection Control And Hospital Epidemiology 2024, 45: 790-792. PMID: 38374787, PMCID: PMC11102821, DOI: 10.1017/ice.2024.27.Peer-Reviewed Original Research